There are currently 163 clinical trials in Shreveport, Louisiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Louisiana State University Health Sciences Center-Shreveport /ID# 144437, LSU Health Sciences Center at Shreveport, Veterans Affairs Medical Center - Shreveport and Louisiana Research Center, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Louisiana Research Center LLC, Shreveport, Louisiana
Conditions: NASH - Nonalcoholic Steatohepatitis
Coflex PS3 Actual Conditions for Use Study
Recruiting
A 2 and 5 year evaluation of clinical outcomes in the treatment of degenerative spinal stenosis with concomitant low back pain by decompression with additional stabilization using the coflex® Interlaminar Technology for FDA Actual Conditions of Use Study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Spine Institute of Louisiana, Shreveport, Louisiana
Conditions: Spinal Stenosis Lumbar
BlueWind RENOVA iStim™ System for the Treatment of OAB
Recruiting
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
12/29/2023
Locations: Regional Urology, LLC, Shreveport, Louisiana
Conditions: Treatment of Patients Suffering From Overactive Bladder (OAB)
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
Recruiting
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: Willis-Knighton Cancer Center, Shreveport, Louisiana
Conditions: EGFRI Induced Acneiform Lesions
OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study
Recruiting
The objective of this clinical study is to compare OSTEOAMP SELECT Fibers to Infuse Bone Graft, in terms of effectiveness and safety, when used as a bone graft substitute in in skeletally mature patients qualified for 2-lumbar interbody fusion (LIF) by means of an intra-patient control model.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
08/25/2023
Locations: Spine Institute of Louisiana, Shreveport, Louisiana
Conditions: Lumbar Spine Disease, Lumbar Spondylolisthesis, Lumbar Spine Instability, Lumbar Spondylosis, Degenerative Disc Disease
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: Spine Institute of Louisiana, Shreveport, Louisiana
Conditions: Symptomatic Cervical Disc Disease
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: Louisiana Clinical Research, Shreveport, Louisiana
Conditions: Schizophrenia